Stéphane Bancel

Chief Executive Officer, Moderna

MA in Engineering, École Central Paris; MSc in Chemical Engineering, University of Minnesota; MBA, Harvard Business School. President and Chief Executive Officer, Moderna Therapeutics, a biotechnology company that researches and develops protein therapies based on novel messenger RNA technology. Former: Executive Director, Global Manufacturing Strategy and Supply Chain, Eli Lilly, Indianapolis, Indiana; Managing Director, Eli Lilly, Belgium; Chief Executive Officer, bioMérieux, a world leader in the diagnostics industry. Supervisory Director, Qiagen; Executive Chairman of the Board, BG Medicine; Member, Board of Directors, Syros Pharmaceuticals. Named as an inventor on over 45 patent application filings in the field of messenger RNA technology. Recipient of honours and awards, including: best CEO for investor relations in France (2009); ranked the number one CEO in the biotech sector, 2011 Thomson Reuters EXTEL Study.

世界経済フォーラムについて

エンゲージメント

  • サインイン
  • パートナー(組織)について
  • 参加する(個人、組織)
  • プレスリリース登録
  • ニュースレター購読
  • 連絡先 (英語のみ)

リンク

言語

プライバシーポリシーと利用規約

サイトマップ

© 2024 世界経済フォーラム